Trials
2 active
8 in total · 1 in the EU
What this is
- How it works
- How it works isn't classified yet
- How it’s given
- “Participants will receive IM injection of 6-valent OspA-based Lyme disease vaccine”In the company’s words, NCT07226882 on ClinicalTrials.gov
- Tested for
- Lyme Disease, Lyme Borreliosis
- Main trialPhase 3
- “The purpose of this study is to learn about the safety effects of the Lyme disease vaccine (called VLA15), and its ability to protect people from Lyme disease after a 5th dose of the vaccine. This study is seeking participants who: * are generally healthy and 7 years of age and older, * have already been vaccinated with 4 doses of VLA15 (from the VALOR study), and have blood sample taken post dose 4. * are not currently taking, or haven't recently taken, medicines like chemotherapy, blood products, or blood thinners. * are not pregnant or breastfeeding and do not plan to become pregnant…”In the company’s words, NCT07500506 on ClinicalTrials.gov
- Other names
- PF-07307405
Other drugs for Lyme Disease
- LotilanerTarsus Pharmaceuticals, Inc. · Phase 2
- MRNA-1982Moderna · Phase 2
- Saccharomyces boulardii CNCM I-745Biocodex · Marketed (Phase 4 trial)
Coming up2
- 4 DecPhase 3 trial completes · ClinicalTrials.gov
- 27 Jan 2028Phase 3 trial completes · ClinicalTrials.gov
Changes0
Last 90 daysNo changes yet. We started recording changes on 6 Nov 2026.
Trials8
| Trial | Phase | Completes | What it tests |
|---|---|---|---|
| Phase 3Recruiting | 4 Dec 2026 | A Study to Learn About the Safety, Tolerability, and Immunogenicity of a Fifth Dose of 6-Valent OspA-Based Lyme Disease Vaccine | |
| Phase 3Active, not recruiting | 27 Jan 2028 | A Study to Learn About Different Dosing Schedules of a Lyme Disease Vaccine in Healthy Adults | |
| Phase 3Completed | 21 Jul 2025 | Safety Study of a Vaccine to Help Protect Against Lyme Disease in Healthy Children | |
| Phase 3Completed | 7 Jan 2026 | An Efficacy, Safety, Tolerability, Immunogenicity, and Lot-Consistency Clinical Trial of a 6-Valent OspA-Based Lyme Disease Vaccine (VLA15) | |
| Phase 2Completed | 18 Dec 2019 | Immunogenicity and Safety Study of a Vaccine Against Lyme Borreliosis, in Healthy Adults Aged 18 to 65 Years. Randomized, Controlled, Observer-blind Phase 2 Study. | |
| Phase 2Completed | 7 Apr 2020 | Alternative Schedule Study For VLA15, a Vaccine Candidate Against Lyme Borreliosis | |
| Phase 2Completed | 25 Mar 2022 | Phase 2 Study Of VLA15, A Vaccine Candidate Against Lyme Borreliosis, In A Healthy Pediatric And Adult Study Population | |
| Phase 1Completed | 28 Sep 2017 | Study Assessing the Safety, Immunogenicity and Dose Response of VLA15, A New Vaccine Candidate Against Lyme Borreliosis |
A trial in both registries shows both numbers.
About
- Sources
- ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026